Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
about
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapyA P2X receptor-mediated nociceptive afferent pathway to lamina I of the spinal cordCrucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia.Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cellsThe h-P2X3 glycoprotein receptor as an example of integrating bioinformatics and structural research.Purinergic signaling regulates neural progenitor cell expansion and neurogenesisSynaptic P2X7 and oxygen/glucose deprivation in organotypic hippocampal cultures.Bilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cellsNeutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface.Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infectionsNTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.The M2-muscarinic receptor inhibits the development of streptozotocin-induced neuropathy in mouse urinary bladder.N-glycoproteome of E14.Tg2a mouse embryonic stem cellsRole of Purinergic Signaling in Voiding Dysfunction.Visceral pain: the neurophysiological mechanismPhosphorylation of beta-catenin by PKA promotes ATP-induced proliferation of vascular smooth muscle cells.Northern Ring Conformation of Methanocarba-Adenosine 5'-Triphosphate Required for Activation of P2X Receptors.Features of adenosine metabolism of mouse heartPhysiology of nucleoside transporters: back to the future. . . .Modulation of purinergic signaling by NPP-type ectophosphodiesterases.Dynamic purine signaling and metabolism during neutrophil-endothelial interactionsEctonucleotidase expression profile and activity in human cervical cancer cell lines.PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases.Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cellsATP overflow in skeletal muscle 1A arterioles.UTP and ATP increase extracellular signal-regulated kinase 1/2 phosphorylation in bovine chromaffin cells through epidermal growth factor receptor transactivation.Functional activity of varicose human great saphenous vein at different sites.Purinergic component of mechanosensory transduction is increased in a rat model of colitis.Alteration of synaptic activity-regulating genes underlying functional improvement by long-term exposure to an enriched environment in the adult brain.P2X receptor ligands and pain.P2Y1 Receptors - Properties and Functional Activities.
P2860
Q24629255-905D503D-5072-4F97-A5DD-96963738681EQ24806550-5B497F4C-208B-404C-9F7D-03AE629FE243Q24817161-74B0A6C8-4B0D-44FD-9DAC-BBCF27094A07Q28570384-00B52B6E-E415-4368-90AA-E3E72CBDFE6BQ30428280-C5DC9B4A-6D40-43CF-9FAD-1B27A4049854Q30479788-5814D5AA-F85F-4626-B600-59B5BEF5EA32Q33201682-B94011BC-26DC-462B-B87E-930BA71C8272Q33581458-34F2DDAE-ABA3-4D44-BE3A-1CFE98925794Q34011327-191F7E05-8F24-4BCF-9C4C-58365AA1FEFFQ34074636-484C69B3-F309-438C-AB27-1AED4F969BD5Q34123241-B2EB9534-370D-4F66-A62B-B8F54754D5A0Q34214668-7F213CDE-2891-4A2B-8E0E-3E845E2F2348Q34584452-DEC35622-1CE5-424B-BE2B-B43458C3AC24Q34973917-E09DD304-A86B-4085-BB72-C5515CBAC4A5Q35164413-4BF763EB-CBD7-45F0-873E-2CBEFC144C21Q35890950-933D0466-F879-4F17-9C98-4A0F43C4B16EQ36108563-C0F46F0F-C5BE-4322-AD53-51D5D6A8EDD7Q36174055-AC90E6CB-868A-47E8-8131-D25983E74E0EQ37082372-EB98B45D-2019-4BF1-8524-C09E52549D1DQ37135548-3D0B6D57-DC8F-4C86-B033-4EBF15904BA5Q37135563-CAB42E73-CDED-4D2D-BF91-B17AC8D11B77Q39008567-D94C659D-2CFF-4037-AA2B-E4133EED4E8BQ41881526-EA936B32-81F7-4C16-ADCB-A2FFE0F217DEQ42427923-0C354C20-044B-4140-86F3-30E14D80C8A6Q43010464-EF5405FE-42BE-4FB8-88CA-2DE12BACAF31Q43083259-6BA3DEEB-6267-422C-9EFF-27068BBBB14AQ43842311-908CB22D-942F-4C09-AB5B-B5DBD6622373Q45032136-3EAAD3A9-91EF-4859-A09F-61D8A53586B4Q46946361-FC6D7A3C-1639-4273-91EA-BD1600D1A930Q48460330-49FA8EE5-BDC3-4E31-A63F-593F31905AE9Q50578303-7F126813-6D49-41B8-88C6-7A1D952CBB95
P2860
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@ast
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@en
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@nl
type
label
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@ast
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@en
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@nl
prefLabel
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@ast
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@en
Potential therapeutic targets in the rapidly expanding field of purinergic signalling.
@nl
P1433
P1476
Potential therapeutic targets in the rapidly expanding field of purinergic signalling
@en
P2093
G Burnstock
P356
10.7861/CLINMEDICINE.2-1-45
P577
2002-01-01T00:00:00Z